Neonatal development of hepatic UGT1A9: Implications of pediatric pharmacokinetics

Drug Metabolism and Disposition

Volumn 40, Issue 7, 2012, Pages 1321-1327

  Miyagi, Shogo J ^a   Milne, Alison M ^b   Coughtrie, Michael W H ^b   Collier, Abby C ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A9; HYMECROMONE; ISOENZYME; NIFLUMIC ACID; PROPOFOL;

ADULT; ALLOMETRY; ARTICLE; CHILD; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME DEVELOPMENT; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SUBSTRATE; ENZYME SYNTHESIS; ENZYMOLOGY; ETHNICITY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; LIVER CLEARANCE; MALE; NEWBORN; PEDIATRIC PHARMACOKINETICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ENZYME INHIBITORS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; HYMECROMONE; INFANT; INFANT, NEWBORN; LIVER; MALE; MICROSOMES, LIVER; MIDDLE AGED; NIFLUMIC ACID; YOUNG ADULT;

EID: 84862702300     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043752     Document Type: Article

References (40)

1. Anderson BJ and Holford NHG (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25-36.
2. Anderson GD (2010) Developmental pharmacokinetics. Semin Pediatr Neurol 17:208-213.
3. Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, and Staels B (2003) The UDP- glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem 278: 13975-13983.
4. Barter ZE, Chowdry JE, Harlow JR, Snawder JE, Lipscomb JC, and Rostami-Hodjegan A (2008) Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab Dispos 36:2405-2409.
5. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, et al. (2010) An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 16:333-343.
6. Bock KW (2010) Functions and transcriptional regulation of adult human hepatic UDP-glucuronosyl- transferases (UGTs): mechanisms responsible for interindividual variation of UGT levels. Biochem Pharmacol 80:771-777.
7. Chien S, Wells TG, Blumer JL, Kearns GL, Bradley JS, Bocchini JA Jr, Natarajan J, Maldonado S, and Noel GJ (2005) Levofloxacin pharmacokinetics in children. J Clin Pharmacol 45:153-160.
8. Collier AC, Ganley NA, Tingle MD, Blumenstein M, Marvin KW, Paxton JW, Mitchell MD, and Keelan JA (2002) UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol 63:409-419.
9. Collier AC, Tingle MD, Keelan JA, Paxton JW, and Mitchell MD (2000) A highly sensitive fluorescent microplate method for the determination of UDP-glucuronosyl transferase activity in tissues and placental cell lines. Drug Metab Dispos 28:1184-1186.
10. Edginton AN, Schmitt W, and Willmann S (2006) Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 45:1013-1034.
11. Gardner-Stephen DA and Mackenzie PI (2007) Hepatocyte nuclear factor1 transcription factors are essential for the UDP-glucuronosyltransferase 1A9 promoter response to hepatocyte nuclear factor 4alpha. Pharmacogenet Genomics 17:25-36.
12. Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, and Houston JB (2006) Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533-539.
13. Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250-267.
14. Kalthoff S, Ehmer U, Freiberg N, Manns MP, and Strassburg CP (2010) Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 139:1699-1710.e1-2.
15. Kawade N and Onishi S (1981) The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in the human liver. Biochem J 196:257-260.
16. Mackenzie PI (2000) Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit 22:10-13.
17. McNamara PJ and Alcorn J (2002) Protein binding predictions in infants. AAPS PharmSci 4:E4.
18. Milne AM, Burchell B, and Coughtrie MW (2011) A novel method for the immunoquantification of UDP-glucuronosyltransferases in human tissue. Drug Metab Dispos 39:2258-2263.
19. Miners JO, Bowalgaha K, Elliot DJ, Baranczewski P, and Knights KM (2011) Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644-652.
20. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
21. Miyagi SJ and Collier AC (2007) Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos 35:1587-1592.
22. Miyagi SJ and Collier AC (2011) The development of UDP- glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos 39:912-919.
23. Murat I, Billard V, Vernois J, Zaouter M, Marsol P, Souron R, and Farinotti R (1996) Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. Anesthesiology 84:526-532.
24. Onishi S, Kawade N, Itoh S, Isobe K, and Sugiyama S (1979) Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver. Biochem J 184:705-707.
25. Peeters MY, Prins SA, Knibbe CA, DeJongh J, van Schaik RH, van Dijk M, van der Heiden IP, Tibboel D, and Danhof M (2006) Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 104:466-474.
26. Posnett DN, McGrath H, and Tam JP (1988) A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor beta-chain. J Biol Chem 263:1719-1725.
27. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
28. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147.
29. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
30. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
31. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1999) UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
32. Strassburg CP, Strassburg A, Kneip S, Barut A, Tukey RH, Rodeck B, and Manns MP (2002) Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50:259-265.
33. Sutherland L, bin Senafi S, Ebner T, Clarke DJ, and Burchell B (1992) Characterisation of a human bilirubin UDP-glucuronosyltransferase stably expressed in hamster lung fibroblast cell cultures. FEBS Lett 308:161-164.
34. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM, and Mondick J (2008) Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol 62: 1027-1037.
35. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
36. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, and Miners JO (2004) Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413-423.
37. Vandermeersch E, Van Hemelrijck J, Byttebier G, and Van Aken H (1989) Pharmacokinetics of propofol during continuous infusion for pediatric anesthesia. Acta Anaesthesiol Belg 40:161-165.
38. Villeneuve L, Girard H, Fortier LC, Gagné JF, and Guillemette C (2003) Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 307:117-128.
39. Wang Y, Moss J, and Thisted R (1992) Predictors of body surface area. J Clin Anesth 4:4-10.
40. Zaya MJ, Hines RN, and Stevens JC (2006) Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos 34:2097-2101.